PTPN11 and ovarian cancer: The clinical implications of these findings are substantial, especially given the suboptimal outcomes in platinum-resistant ovarian cancer (PROC) (Eskander et al., 2023; Leung and Konstantinopoulos, 2021; Naumann and Coleman, 2011) The ability of TWP to simultaneously inhibit EGFR, JAK-STAT, PTPN11, and androgen signaling pathways suggests strong potential for synergy with existing targeted therapies.